{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:19:50Z","timestamp":1792786790900,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"XBiotech","id":[{"id":"https:\/\/ror.org\/035b6vx73","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jid.2019.10.024","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T19:42:09Z","timestamp":1580240529000},"page":"1538-1545.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-8618","authenticated-orcid":false,"given":"Alice","family":"Gottlieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1655-3411","authenticated-orcid":false,"given":"Nicola E.","family":"Natsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-8733","authenticated-orcid":false,"given":"Francisco","family":"Kerdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-1856","authenticated-orcid":false,"given":"Seth","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-4516","authenticated-orcid":false,"given":"Edgar","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-4990","authenticated-orcid":false,"given":"Gilberto","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1386-5076","authenticated-orcid":false,"given":"Liliam","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6924-6736","authenticated-orcid":false,"given":"Jessica","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5926-8034","authenticated-orcid":false,"given":"Giancarlo","family":"Guido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1197-1403","authenticated-orcid":false,"given":"Kathryn","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3355-0597","authenticated-orcid":false,"given":"Diego","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5183-5433","authenticated-orcid":false,"given":"Michael","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-9294","authenticated-orcid":false,"given":"Chad","family":"Babcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-3054","authenticated-orcid":false,"given":"John","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2019.10.024_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003470","article-title":"The structural pathway of interleukin 1 (IL-1) initiated signaling reveals mechanisms of oncogenic mutations and SNPs in inflammation and cancer","volume":"10","author":"Acuner Ozbabacan","year":"2014","journal-title":"PLOS Comput Biol"},{"key":"10.1016\/j.jid.2019.10.024_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaad.2009.02.013","article-title":"Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity","volume":"61","author":"Canoui-Poitrine","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2019.10.024_bib3","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1172\/JCI28075","article-title":"MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals","volume":"116","author":"Chen","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2019.10.024_bib4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ni.3503","article-title":"Interleukin 1\u03b1 and the inflammatory process","volume":"17","author":"Di Paolo","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2019.10.024_bib5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2019.10.024_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2340\/00015555-1082","article-title":"Psychosocial impact of hidradenitis suppurativa: a qualitative study","volume":"91","author":"Esmann","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2019.10.024_bib7","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/ATVBAHA.118.311150","article-title":"Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1\u03b1 and cathepsin G","volume":"38","author":"Folco","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jid.2019.10.024_bib8","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.4049\/jimmunol.157.6.2506","article-title":"Respiratory syncytial virus infection of human respiratory epithelial cells up-regulates class I MHC expression through the induction of IFN-beta and IL-1 alpha","volume":"157","author":"Garofalo","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2019.10.024_bib9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","article-title":"An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa","volume":"158","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2019.10.024_bib10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1\u03b1 in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2019.10.024_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/infdis\/162.1.215","article-title":"Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in\u00a0vitro and a circulating TNF-like activity in rabbits","volume":"162","author":"Ikejima","year":"1990","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jid.2019.10.024_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: A randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.10.024_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130522","article-title":"Compartmentalized cytokine responses in hidradenitis suppurativa","volume":"10","author":"Kanni","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jid.2019.10.024_bib14","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1182\/blood.V81.10.2492.2492","article-title":"Activated platelets induce endothelial secretion of interleukin-8 in\u00a0vitro via an interleukin-1-mediated event","volume":"81","author":"Kaplanski","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.10.024_bib15","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2019.10.024_bib16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jid.2019.10.024_bib17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2019.10.024_bib18","first-page":"1017","article-title":"Hidradenitis suppurativa: review of the pathogenesis and treatment","volume":"15","author":"Kurayev","year":"2016","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jid.2019.10.024_bib19","doi-asserted-by":"crossref","first-page":"1551651","DOI":"10.1080\/2162402X.2018.1551651","article-title":"Inteleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1\u03b1 antibody, in a phase III randomized study of advanced colorectal cancer","volume":"8","author":"Kurzrock","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jid.2019.10.024_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2019.10.024_bib21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaad.2016.08.036","article-title":"Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa","volume":"76","author":"Montaudi\u00e9","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2019.10.024_bib22","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","article-title":"Hidradenitis suppurativa","volume":"23","author":"R\u00e9vuz","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2019.10.024_bib23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","article-title":"Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies","volume":"59","author":"R\u00e9vuz","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2019.10.024_bib24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2353\/ajpath.2007.060657","article-title":"The toll-like receptor adaptor proteins MyD88 and Mal\/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis","volume":"170","author":"Sacre","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jid.2019.10.024_bib25","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/jdv.14389","article-title":"Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa","volume":"31","author":"Thomi","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2019.10.024_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: A randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2019.10.024_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1468-3083.2000.00087.x","article-title":"The natural history of hidradenitis suppurativa","volume":"14","author":"Von der Werth","year":"2000","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2019.10.024_bib29","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 Pathway Is Hyperactive in Hidradenitis suppurativa and Contributes to Skin Infiltration and Destruction","volume":"139","author":"Witte-H\u00e4ndel","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.10.024_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/biom9080345","article-title":"IL-38: A new player in inflammatory autoimmune disorders","volume":"9","author":"Xie","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.jid.2019.10.024_bib31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.5114\/ada.2017.65626","article-title":"Increased serum interleukin-6 levels in patients with hidradenitis suppurativa","volume":"34","author":"Xu","year":"2017","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jid.2019.10.024_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital anxiety and Depression Scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jid.2019.10.024_bib34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20300713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20300713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:17:36Z","timestamp":1758302256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X20300713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0022202X20300713"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2019.10.024","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2019.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}